From Geert: This is the best piece of ‘scientific’ propaganda I’ve seen to make people believe that the dramatic evolution of the virus is not driven by population-level S-directed immune pressure caused by mass vaccination with S-based vaccines!
“Subject to further clarification, on-going eligibility in 2022/23, after the one off-programme, is expected to be for children in the academic years where children are aged 11 or 12 years.”
From Geert: I predict that the cases in mammalian species (including humans) will grow over winter. In addition, I am not sure whether spill-over cases of avian flu (or enzootic flu in general) always cause disease. I recently posted an article on my website postulating that the immune response in highly vaccinated populations could render monkeypox virus, but also enzootic flu, largely asymptomatic. In that case, symptomatic cases in humans and other mammalian species would only point to the tip of the iceberg. I must say, though, that I don't feel very reassured by the statement made in this press release:
"The virus has some features that make further study and follow-up on mammalian cases important, but the virus does not currently contain the features we know are required for transmission between humans and likely other mammalian hosts." "In addition, the recent discovery of HPAIV in a porpoise in Sweden almost certainly suggests that the Florida dolphin finding isn't a one-off, unique event".
How can we say that the virus has some 'features' that prevent transmission between humans and other mammalian species if we have no clue about potential asymptomatic transmission. It has recently been reported that the rapid and widespread dissemination of Monkeypox virus (in highly vaccinated countries!) was also rooted in asymptomatic transmission....
From Geert: I am very worried about the monkeypox (MP) vaccination strategy. Vaccination of substantial cohorts is only going to increase the rate of asymptomatic infections. As explained in a previous contribution of mine (on my website), this is likely to result in natural selection of more infectious immune escape variants in vaccinees (this particularly applies to non-replicating vaccines, which are the ones currently used). Higher infection rates lead to higher morbidity rates, which simply increase the part of the population that exerts immune pressure on viral infectiousness (and therefore promotes immune escape).
So, we may end up with circulating MP virus that no longer matches the vaccinal antibodies very well. This implies an increased risk for vaccinees to contract antibody-dependent enhancement of disease. It’s not just a theoretical assumption (see link attached): " Significant mutation in the monkeypox virus that resulted in at least three infected Californians who were initially given "false negative results". That's why I am strongly advising against getting yourself vaccinated against MP‼
From Geert: This is not taking into account the type of mutations one can reasonably expect to occur in the next generation of 'more virulent' variants. I have been predicting that the latter will primarily use changes in their glycosylation to overcome population-level immune pressure currently exerted on viral virulence. It's highly unlikely that the miraculous monoclonals will even be able to reach the critical neutralizing sites within spike protein. The keyword is 'steric hindrance'. One of the key roles of glycans grafted on viral proteins is to hide/ mask vulnerable domains!
“The governor’s emergency order aims to bolster the state’s vaccination effort by making it easier for parents to get children vaccinated without needing to see a doctor. Now, pharmacists, paramedics and midwives will be able to dispense the vaccine, too.”
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.